Valiant W.L. Mak

Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients

Miao Hu, Sandra S.H. Lui, Valiant W.L. Mak et al. · Pharmacogenetics and Genomics · 2010 · 48 citations

Life Sciences, Genetics, Pharmacology +17

Effects of Grapefruit Juice and SLCO1B1 388A>G Polymorphism on the Pharmacokinetics of Pitavastatin

Miao Hu, Valiant W.L. Mak, Ophelia Yin et al. · Drug Metabolism and Pharmacokinetics · 2012 · 24 citations

Medicine, Pharmacokinetics, Pharmacology +6

Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease

Miao Hu, Valiant W.L. Mak, Tom Chu et al. · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · 2009 · 21 citations

Medicine, Pharmacokinetics, Pharmacology +17

Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia

Miao Hu, Valiant W.L. Mak, Brian Tomlinson · Pharmacogenetics and Genomics · 2012 · 19 citations

Life Sciences, Genetics, Molecular Genetics +16

Effect of Central Obesity, Low High-Density Lipoprotein Cholesterol and C-Reactive Protein Polymorphisms on C-Reactive Protein Levels During Treatment With Rosuvastatin (10 mg Daily)

Miao Hu, Michael H.K. Lee, Valiant W.L. Mak et al. · The American Journal of Cardiology · 2010 · 17 citations

Pharmacy, Pharmacotherapy, Cardiovascular Pharmacotherapy +9